A Retrospective Clinical Study on the Adjuvant Treatment of Glioblastoma After Simultaneous Radiotherapy With Anti-angiogenesis Drugs Combined With Temozolomide
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 25 Apr 2019 Planned number of patients changed from 50 to 60.
- 22 Apr 2019 Planned End Date changed from 1 Apr 2019 to 1 Oct 2019.